When considering treatment of patients suffering from PSCA-positive cancers with anti-PSCA-RICIA, it can be predicted that tumorigenic as well as normal cells expressing PSCA at sufficient surface levels and containing TLR3 are affected by anti-PSCA-RICIA. This evidence concerns the gene TLR3 and cancer.